EUVIMEDEUVIMED entdecken
Crossref

Bioequivalence assessment of two formulations of empagliflozin in healthy adult subjects

Evelyn Pena, Alfredo Inatti, Anyoli Taly, José Gregorio Chacón, Xenon Serrano-Martin

American Journal of Pharmacotherapy and Pharmaceutical Sciences · 2023

DOI: 10.25259/ajpps_2023_019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Pharmacotherapy and Pharmaceutical Sciences, 2023. Verfasst von Evelyn Pena und 4 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The objective of the study was to evaluate the bioequivalence (BE) between Izaban® (test) and Jardiance® (reference) empagliflozin 25 mg, oral tablets, in healthy adult subjects. Materials and Methods: A randomized, open-label, two-sequence, and two-period crossover comparative oral bioavailability study was conducted on healthy adult subjects. It was tested BE in vivo using a comparative pharmacokinetic (PK) evaluation. Serial blood samples were collected up to 72 h following oral administration of the study drugs, plasma concentrations of empagliflozin were using liquid chromatography mass spectrometry (LC-MS-MS) method.

Results

The test and reference drug products were considered bioequivalent when the geometric means of the test (T)/reference (R) ratios and 90% confidence intervals (CIs) fall within the range of 80.00–125.00%. For PK parameters, % T/R ratios and 90% CIs were C max : 105.11% (100.28–110.18%), area under curve (AUC 0-t ): 103.25% (99.62–107.00%), and AUC 0-∞ 102.71% (99.26–106.28%).

Conclusion

Our study demonstrated in vivo BE between the two empagliflozin formulations tested in healthy subjects under fasting conditions.

Zitieren

APA

Pena, E., Inatti, A., Taly, A., Chacón, J. G., & Serrano-Martin, X. (2023). Bioequivalence assessment of two formulations of empagliflozin in healthy adult subjects. American Journal of Pharmacotherapy and Pharmaceutical Sciences. https://doi.org/10.25259/ajpps_2023_019

Vancouver

Pena E, Inatti A, Taly A, Chacón JG, Serrano-Martin X. Bioequivalence assessment of two formulations of empagliflozin in healthy adult subjects. American Journal of Pharmacotherapy and Pharmaceutical Sciences. 2023. doi:10.25259/ajpps_2023_019

BibTeX
@article{Pena2023,
  author = {Pena, Evelyn and Inatti, Alfredo and Taly, Anyoli and Chacón, José Gregorio and Serrano-Martin, Xenon},
  title = {Bioequivalence assessment of two formulations of empagliflozin in healthy adult subjects},
  journal = {American Journal of Pharmacotherapy and Pharmaceutical Sciences},
  year = {2023},
  doi = {10.25259/ajpps_2023_019}
}
Kostenlos starten →